Imagine a weekly shot that could help manage weight. Researchers just took a very early look at one possibility. In a 12-week study of 100 people with obesity or overweight, a new drug called eloralintide was tested at different doses. The goal was to see if it was safe, how the body processed it, and if it had any effect on weight.
The findings show the drug was generally well-tolerated. The most common side effects were decreased appetite, headache, and fatigue. Gastrointestinal issues like diarrhea and nausea were reported but were described as minimal. On the weight front, people taking the drug saw their body weight drop by an average of 2.6% to 11.3%, depending on the dose, while those on a placebo did not.
It's crucial to hold the excitement. This was a Phase 1 study, which is the earliest stage of human testing. Its main job is to check safety, not prove a treatment works. With only 100 people and a follow-up of just three months, we don't know if the weight loss would last or what the long-term safety profile looks like. The results are a promising signal, but much larger and longer studies are needed to know if this could become a real option.